BD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis

Rhea-AI Summary

BD (NYSE: BDX) has received 510(k) clearance from the FDA for its BD Vaginal Panel on the BD COR™ System, a diagnostic test that detects the three most common causes of vaginitis using a single swab. This test improves detection accuracy for conditions like bacterial vaginosis and vulvovaginal candidiasis, ensuring proper treatment and helping reduce misdiagnoses. The BD Vaginal Panel is the first high-throughput version of its kind, further enhancing BD's commitment to women's health diagnostics. The BD COR™ System allows high-volume testing, significantly improving laboratory efficiency and patient management.

Positive

• 510(k) clearance from the FDA for the BD Vaginal Panel enhances BD's product portfolio.
• The BD Vaginal Panel ensures accurate diagnosis and improves treatment for women with vaginitis.
• High-throughput capabilities of the BD COR™ System allow rapid sample processing, enhancing lab efficiency.

Negative

• None.

BD Vaginal Panel on BD COR™ System Tests for Multiple Common Types of Vaginitis Using Only One Swab, One Test

FRANKLIN LAKES, N.J., March 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System, a comprehensive diagnostic test that directly detects the three most common infectious causes of vaginitis using BD's high-throughput molecular diagnostic platform for large laboratories.

Originally granted marketing authorization for the BD MAX™ System in 2016, the BD Vaginal Panel is the first microbiome-based polymerase chain reaction (PCR) assay that uses a single swab and test to simultaneously detect organisms associated with bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and Trichomonas vaginalis (TV), and reports a clear positive or negative result for each condition separately. This 510(k) clearance for the BD Vaginal Panel on the BD COR™ System is the first high-throughput version of the test. Accurate diagnosis of BV, VVC and TV is critical to ensuring appropriate treatment regimens and decreasing the risk of associated complications and resistance to treatment. Using a single test can also help reduce the need for repeat testing unnecessary use of treatments and lower the risk of contracting STIs.

"Most women have a vaginal infection during their lifetime and millions of them receive inadequate treatment," said Nikos Pavlidis, vice president of Diagnostics for BD. "A recent study showed that four out of 10 women didn't receive the appropriate diagnosis and treatment for their vaginitis symptoms after an initial physician visit, which led to four out of 10 women having to schedule a new appointment because of persistent symptoms. The BD Vaginal Panel can help end the cycle of repeat visits, misdiagnosis and ineffective treatment for the millions of women suffering from vaginitis."

If a test is positive for VVC (commonly referred to as a "yeast infection"), the BD Vaginal Panel is the only FDA-cleared Nucleic Acid Amplification Test (NAAT) that provides separate results for C. glabrata and C. krusei — two Candida species that are known to carry resistance to traditional antimicrobials — to ensure proper treatments are prescribed.

The availability of the BD Vaginal Panel on the automated BD COR™ System in the U.S. reflects BD's commitment to expand the menu of available assays for women's health and other infectious diseases.

The BD Vaginal Panel is the third assay available for use on the BD COR™ System in the U.S. The first being the BD Onclarity™ HPV assay (the only FDA-approved HPV test with extended genotyping that can individually identify and report HPV genotypes including HPV 16, 18 and 31, which have the highest contribution to cervical precancer and cancer). The second was the BD CTGCTV2 molecular assay, a single test that detects from one sample the three most prevalent non-viral sexually transmitted infections (STIs) — Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV). These STIs can also have overlapping symptoms making one test to identify all three important for patient care. With the clearance of BD Vaginal Panel on the BD COR™ System, labs can now offer physicians both BD Vaginal Panel and BD CTGCTV2 testing from one swab and one patient collection.

The BD COR™ System is the only high-throughput, fully integrated preanalytical and analytical system on the market, providing access to critical women's health and STI testing by enhancing both laboratory operations and patient management with advanced molecular diagnostic capabilities. The BD COR™ System allows 1,700 specimens to be loaded at a time, with onboard capacity for reagents and samples that provide more than eight hours of unimpeded system processing. The system is capable of delivering nearly 2,000 sample results in 24 hours, eliminating multiple manual interactions per shift that were traditionally required.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:
Media:	Investors:
Troy Kirkpatrick	Francesca DeMartino
VP, Public Relations	SVP, Head of Investor Relations
858.617.2361	201.847.5743
troy.kirkpatrick@bd.com	francesca.demartino@bd.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-receives-fda-510k-clearance-for-first-of-its-kind-high-throughput-diagnostic-test-for-infectious-vaginitis-301773489.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What is the BD Vaginal Panel and what does it detect?

The BD Vaginal Panel is a diagnostic test that detects bacterial vaginosis, vulvovaginal candidiasis, and Trichomonas vaginalis using a single swab.

When did BD receive FDA clearance for the BD Vaginal Panel?

BD received FDA 510(k) clearance for the BD Vaginal Panel on March 16, 2023.

How does the BD COR™ System enhance laboratory operations?

The BD COR™ System provides high-throughput capabilities, allowing for nearly 2,000 sample results in 24 hours and reducing manual processes.

What is the significance of the BD Vaginal Panel for women's health?

The BD Vaginal Panel improves diagnostic accuracy and treatment for common vaginal infections, reducing the risk of complications and misdiagnosis.

Is the BD Vaginal Panel the first of its kind?

Yes, it is the first microbiome-based PCR assay that uses a single swab for simultaneous detection of multiple vaginitis causes.